Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JWK012 is an investigational gene therapy developed by West China Hospital of Sichuan University for the treatment of treatment-resistant depressive disorder (TRD). The therapy consists of an adeno-associated virus serotype 9 (AAV9) vector encoding transforming growth factor-beta (TGF-β), administered as a nasal spray. This approach aims to bypass the blood-brain barrier to deliver the therapeutic gene directly to the central nervous system. JWK012 is specifically being evaluated in patients with TRD who have low plasma levels of TGF-β1, a cytokine implicated in the regulation of neuroinflammation and neuroplasticity, which are often disrupted in depressive disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JWK012.